Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactiv...
Nadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction.
2nd Department of Anesthesiology and Critical Care, Medical University of Lublin, Lublin, Lubelskie, Poland
Anhui Provincial Hospital, Hefei, Anhui, China
Shanghai 5th People's Hospital, Shanghai, Shanghai, China
Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
Anhui Provincial Hospital, Hefei, Anhui, China
Yantai Yuhuangding Hospital, Yantai, Shangdong, China
Shanghai 5th People's Hospital, Shanghai, Shanghai, China
Leiden University Medical Centre, Leiden, Zuid Holland, Netherlands
Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong
Rijnstate Hospital, Arnhem, Wagnerlaan 55, Netherlands
Neurology Clinic Univeristy Hospital in Martin, Martin, Slovakia
Martini Ziekenhuis, Groningen, Netherlands
Zhongshan Hospital, Shanghai, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.